ArticlemSphere2022
PARIS and SPARTA: Finding the Achilles' Heel of SARS-CoV-2.
Article in mSphere, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Elicitation of neutralizing antibodies and IgG4 subclass switching following booster vaccination with ancestral COVID-19 mRNA vaccines does not reduce breakthrough infections.Human vaccines & immunotherapeutics · 2025Article
- COVID-19 Vaccination Enhances the Immunogenicity of Seasonal Influenza Vaccination in the Elderly.Vaccines · 2025Article
- Antibody evasiveness of SARS-CoV-2 subvariants KP.3.1.1 and XEC.Cell reports · 2025Article
- A Surrogate Enzyme-Linked Immunosorbent Assay to Select High-Titer Human Convalescent Plasma for Treating Immunocompromised Patients Infected With Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern.The Journal of infectious diseases · 2025Article
- Article
- Single-cell transcriptome profile during the antibody decline phase following inactivated COVID-19 vaccination.Frontiers in cellular and infection microbiology · 2025Article
- Robust SARS-CoV-2-neutralizing antibodies sustained through 6 months post XBB.1.5 mRNA vaccine booster.Cell reports. Medicine · 2024Article
- The Landscape of Observational COVID-19 Cohort Studies Funded by the National Institute of Allergy and Infectious Diseases.American journal of epidemiology · 2024Article
- XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1.Cell host & microbe · 2024Article
- Article
- Reduction in Long COVID Symptoms and Symptom Severity in Vaccinated Compared to Unvaccinated Adults.Open forum infectious diseases · 2024Article
- The post-COVID-19 population has a high prevalence of cross-reactive antibodies to spikes from allmBio · 2024Article
- Article
- Article
- Deep immunological imprinting due to the ancestral spike in the current bivalent COVID-19 vaccine.Cell reports. Medicine · 2023Article
- Evolving antibody evasion and receptor affinity of the Omicron BA.2.75 sublineage of SARS-CoV-2.iScience · 2023Article
- Prior SARS-CoV-2 Infection Enhances Initial mRNA Vaccine Response with a Lower Impact on Long-Term Immunity.ImmunoHorizons · 2023Article
- Sequential intrahost evolution and onward transmission of SARS-CoV-2 variants.Nature communications · 2023Article
- Site of vulnerability on SARS-CoV-2 spike induces broadly protective antibody against antigenically distinct Omicron subvariants.The Journal of clinical investigation · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Funding
Abstract
To understand reinfection rates and correlates of protection for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), we established eight different longitudinal cohorts in 2020 under the umbrella of the PARIS (Protection Associated with Rapid Immunity to SARS-CoV-2)/SPARTA (SARS SeroPrevalence And Respiratory Tract Assessment) studies. Here, we describe the PARIS/SPARTA cohorts, the harmonized assays and analysis that are performed across the cohorts, as well as case definitions for SARS-CoV-2 infection and reinfection that have been established by the team of PARIS/SPARTA investigators.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.